 |
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2007, vol. 13, book 1
Subject Collection: Medicine
Page: 74-76
DOI: 10.5272/jimab.2007131.70
Online date: November 15, 2007
J of IMAB 2007; 13(1):74-76
LETROZOLE IN THE TREATMENTOF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER
Deyan N. Davidov,
Department of chemotherapy, Oncological center, Medical University - Pleven, Bulgaria
ABSTRACT:
Backgraund: Approximately 75 % of breast cancers are hormone sensitive, and hormonetherapy is effective for many of these patients. The aim of this study is to evaluate the efficacy and safety of treatment with Letrozole in postmenopausal women with advanced or metastatic breast cancer. Methods: Thirty two postmenopausal women with histologically or cytologically proven breast cancer who presented with either locally advanced or had metastatic breast cancer, entered the study. Tumors were required to be estrogen or progesterone receptor positive. Therapy consists of Letrozole 1 mg daily per os. Results: Thirty two patients were treated in Pleven Medical University- Department of chemotherapy. Three complete responses and seven partial responses were obtained. The main grade toxicity included rush and hot flushes. Conclusions: Letrozole was effective in patients with advanced or metastatic breast cancer with 38.2% response rate and mild to moderate toxicity.
Key words: Breast cancer, Letrozole, Survival.
- Download FULL TEXT (PDF - 551 KB)
Please cite this article as:
Davidov DN. LETROZOLE IN THE TREATMENTOF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER. J of IMAB 2007; 13(1):74-76. doi: 10.5272/jimab.2007131.70
REFERENCES:
1. Jemal A, Tiwari RC, Murray T et all, Cancer Statistics, 2004. CA Cancer J Clin 2004;54:8–29.
2. Glimelius B, Hofman K, Graf W at all, Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Cancer 1994; 73: 556–562.
3. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer 1997; 80: 1179–1187.
4. Meta-analysis Group in Cancer. Efficacy of IV continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–308.
5. Pommier Y, Tanizava A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. In: Liu LF, ed. Advanced in pharmacology. New York: Academic Press 1994; 29B; 73-92
6. Saltz LB, Cox JV, Blanke C et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412
7. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first- line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000; 355: 1371
8. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47; 207-214
9. Brimdage MD, Pater JL, Zee B: Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 1993; 85; 38-48
10. Kaplan EL, Meyer P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959; 53; 457- 481
11. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22; 229-237
12. Goldberg RM, Sargent DJ, Morton RF et all: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxalplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22; 23-30